Hologic (HOLX) Suffers a Larger Drop Than the General Market: Key Insights
In the latest trading session, Hologic (HOLX) closed at $64.14, marking a -1.6% move from the previous day. This move lagged the S&P 500's daily loss of 0.84%. Meanwhile, the Dow experienced a drop of 0.7%, and the technology-dominated Nasdaq saw a decrease of 0.91%.
Coming into today, shares of the medical device maker had gained 14.77% in the past month. In that same time, the Medical sector gained 0%, while the S&P 500 gained 1.44%.
The investment community will be paying close attention to the earnings performance of Hologic in its upcoming release. The company is expected to report EPS of $1.06, unchanged from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $1.01 billion, indicating a 0.39% downward movement from the same quarter last year.
HOLX's full-year Zacks Consensus Estimates are calling for earnings of $4.2 per share and revenue of $4.08 billion. These results would represent year-over-year changes of +2.94% and +1.16%, respectively.
Any recent changes to analyst estimates for Hologic should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.27% decrease. Hologic presently features a Zacks Rank of #4 (Sell).
Looking at its valuation, Hologic is holding a Forward P/E ratio of 15.52. This denotes a discount relative to the industry average Forward P/E of 26.88.
It is also worth noting that HOLX currently has a PEG ratio of 2.39. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Instruments stocks are, on average, holding a PEG ratio of 2.26 based on yesterday's closing prices.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 151, putting it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Hologic, Inc. (HOLX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Sam Altman said none of his 'best people' at OpenAI were enticed by Meta's $100 million signing bonuses
Meta tried to recruit OpenAI's top talent with $100 million signing bonuses, says Sam Altman. Altman said that so far, "none of our best people have decided to take them up on that." Meta recently made a $15 billion investment in data-labeling firm Scale AI. Sam Altman, the CEO of OpenAI, said Meta's attempts to poach his best staff with generous signing bonuses were not successful. Altman talked about the competition OpenAI faces from Meta on his brother's podcast "Uncapped with Jack Altman," in an episode that aired on Tuesday. "I've heard that Meta thinks of us as their biggest competitor, and I think it is rational for them to keep trying. Their current AI efforts have not worked as well as they've hoped," Altman said of Meta's $15 billion investment in data-labeling firm Scale AI. But Altman said he found it "crazy" when Meta tried to recruit OpenAI's employees by offering them $100 million signing bonuses if they jumped ship. "I'm really happy that at least so far, none of our best people have decided to take them up on that," Altman said. "People sort of look at the two paths and say, 'Alright, OpenAI's got a really good shot, a much better shot actually, delivering on superintelligence and also may eventually be the more valuable company,'" he continued. Meta has a $1.77 trillion market capitalization, and OpenAI was last valued at $300 billion in March. Altman said Meta's approach of growing its talent pool by dangling eye-watering pay packages could come at the expense of its culture. "The strategy of a ton of upfront guaranteed comp and that being the reason you tell someone to join, like really the degree to which they're focusing on that and not the work and not the mission, I don't think that's going to set up a great culture," Altman said. "There's many things I respect about Meta as a company, but I don't think they are a company that's like great at innovation," he added. The hunt for AI talent has been heating up as companies seek to dominate the field. Aravind Srinivas, the founder and CEO of AI search startup Perplexity, said in a March 2024 episode of the "Invest Like The Best" podcast that companies must offer "amazing incentives and immediate availability of compute" if they want to hire AI talent. "I tried to hire a very senior researcher from Meta, and you know what they said? 'Come back to me when you have 10,000 H100 GPUs,'" Srinivas said, referencing the AI chips made by Nvidia. Naveen Rao, the vice president of AI at Databricks, said in an interview with The Verge last year that there are fewer than 1,000 researchers who are capable of building frontier AI models. "It's like looking for LeBron James," Rao said. "There are just not very many humans who are capable of that." Representatives for OpenAI and Meta did not respond to requests for comment from Business Insider. Read the original article on Business Insider
Yahoo
26 minutes ago
- Yahoo
BT Group (LON:BT.A) Has Announced That It Will Be Increasing Its Dividend To £0.0576
The board of BT Group plc (LON:BT.A) has announced that the dividend on 10th of September will be increased to £0.0576, which will be 1.2% higher than last year's payment of £0.0569 which covered the same period. This makes the dividend yield about the same as the industry average at 4.3%. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Unless the payments are sustainable, the dividend yield doesn't mean too much. The last payment made up 76% of earnings, but cash flows were much higher. Since the dividend is just paying out cash to shareholders, we care more about the cash payout ratio from which we can see plenty is being left over for reinvestment in the business. The next year is set to see EPS grow by 59.2%. If the dividend continues along recent trends, we estimate the payout ratio will be 44%, which would make us comfortable with the sustainability of the dividend, despite the levels currently being quite high. Check out our latest analysis for BT Group Although the company has a long dividend history, it has been cut at least once in the last 10 years. The dividend has gone from an annual total of £0.124 in 2015 to the most recent total annual payment of £0.0816. Doing the maths, this is a decline of about 4.1% per year. Declining dividends isn't generally what we look for as they can indicate that the company is running into some challenges. With a relatively unstable dividend, it's even more important to evaluate if earnings per share is growing, which could point to a growing dividend in the future. BT Group has seen earnings per share falling at 9.3% per year over the last five years. Declining earnings will inevitably lead to the company paying a lower dividend in line with lower profits. However, the next year is actually looking up, with earnings set to rise. We would just wait until it becomes a pattern before getting too excited. In summary, while it's always good to see the dividend being raised, we don't think BT Group's payments are rock solid. In the past, the payments have been unstable, but over the short term the dividend could be reliable, with the company generating enough cash to cover it. Overall, we don't think this company has the makings of a good income stock. It's important to note that companies having a consistent dividend policy will generate greater investor confidence than those having an erratic one. At the same time, there are other factors our readers should be conscious of before pouring capital into a stock. For instance, we've picked out 3 warning signs for BT Group that investors should take into consideration. Looking for more high-yielding dividend ideas? Try our collection of strong dividend payers. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Washington Post
32 minutes ago
- Washington Post
A judge could advance Purdue Pharma's $7B opioid settlement after all 50 states back it
All 50 U.S. states have agreed to the OxyContin maker Purdue Pharma 's latest plan to settle thousands of lawsuits over the toll of opioids . A judge on Wednesday is being asked to clear the way for local governments and individual victims to vote on it. Government entities, emergency room doctors, insurers, families of children born into withdrawal from the powerful prescription painkiller, individual victims and their families and others would have until Sept. 30 to vote on whether to accept the deal, which calls for members of the Sackler family who own the company to pay up to $7 billion over 15 years.
